PubMed publicaties

Sinds begin jaren 60 zijn er veel wetenschappelijke artikelen gepubliceerd over de schadelijke effecten van Softenon op de ongeboren vrucht en op de ouder wordende Softenon slachtoffers. Een verzameling van de meest recent gepubliceerde artikelen vindt u hieronder. De volledige lijst met titels en abstracts kunt u vinden, door hier te klikken.

2017 Impact Thalidomide use Brazil. Er wordt met een kritische blik gekeken naar de geschiedenis van Thalidomide in Brazilie en naar het voorkomen van Thalidomide Embryopathie in de afgelopen decennia.

2015 Blood pressure in thalidomide-impaired patient. Een publicatie van anesthesie bij een Softenon slachtoffer zonder armen en met benen waarbij ovariumcystectomie wordt uitgevoerd.

Oct 2023 Early experience of thalidomide therapy for high-grade peripheral and facial arteriovenous malformations.
Arteriovenous malformations (AVMs) are developmental defects in the vascular system with abnormal connections between arteries and veins. A minority of AVMs are characterized by aggressive growth and continue to proli...

Dec 2023 Maintenance therapy with a combination of azacitidine, danazol, and thalidomide after intensive chemotherapy in patients with acute myeloid leukemia.
This study aimed to evaluate the efficacy of azacitidine (AZA) combined with danazol (DNZ) and thalidomide (THD) maintenance therapy after intensive chemotherapy (IC) in patients with acute myeloid leukemia (AML).

Nov 2023 Thalidomide for Recurrent Bleeding Due to Small-Intestinal Angiodysplasia.
Recurrent bleeding from the small intestine accounts for 5 to 10% of cases of gastrointestinal bleeding and remains a therapeutic challenge. Thalidomide has been evaluated for the treatment of recurrent bleeding due t...

Oct 2023 Comparison of risankizumab with apremilast for the treatment of moderate psoriasis.

Oct 2023 Efficacy and safety of thalidomide in children with monogenic autoinflammatory diseases: a single-center, real-world-evidence study.
Monogenic autoinflammatory diseases (AIDs) are rare inflammatory diseases caused by genetic variants. The pathogenesis is complex and treatment options are limited. This study aimed to describe the safety and efficacy...

Oct 2023 Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial.
Aponermin, a circularly permuted tumor necrosis factor-related apoptosis-inducing ligand, is a potential death receptor 4/5-targeted antitumour candidate. Previous phase 1/2 studies have demonstrated the efficacy of a...

Jul 2023 [The efficacy and safety of bortezomib, pomalidomide and dexamethasone regimen in the treatment of relapsed/refractory multiple myeloma].

Dec 2023 Cause analysis of conversion to biologics in spondyloarthritis patients with poor response to conventional treatment.
We sought to investigate the reasons why spondyloarthritis (SpA) patients failed to respond to non-steroidal anti-inflammatory drugs (NSAIDs) and conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) ...

Dec 2023 The age-dependent changes in risk weights of the prognostic factors for multiple myeloma.
Multiple myeloma is a highly heterogenous plasma cell malignancy, commonly seen in older patients. Age is one of the important prognostic factors. However, nearly all the prognostic staging systems are based on clinic...

2023 Thalidomide Alleviates Apoptosis, Oxidative Damage and Inflammation Induced by Pemphigus Vulgaris IgG in HaCat Cells and Neonatal Mice Through MyD88.
Thalidomide (Tha) can be used as a selective treatment for mild pemphigus vulgaris (PV). However, the specific mechanism of action remains unclear.